Cargando…

The portal for rare diseases and orphan drugs

Detalles Bibliográficos
Autor principal:	Singh, Jatinder
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Webwise
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669585/ https://www.ncbi.nlm.nih.gov/pubmed/23761721

Ejemplares similares

Guide to Pharmacology
por: Singh, Jatinder
Publicado: (2012)

Randomization and online databases for clinical trials
por: Singh, Jatinder
Publicado: (2014)

Mini Manuscript
por: Singh, Jatinder
Publicado: (2014)

Essential medicines and health products information portal
por: Shankar, P. Ravi
Publicado: (2014)

Protein data bank
por: Parasuraman, S.
Publicado: (2012)

Rare diseases and orphan drugs: Latvian story
por: Logviss, Konstantins, et al.
Publicado: (2014)

Pricing of orphan drugs in oncology and rare diseases
por: Nuijten, Mark, et al.
Publicado: (2020)

The availability and affordability of orphan drugs for rare diseases in China
por: Gong, Shiwei, et al.
Publicado: (2016)

Rare diseases and orphan drugs: 500 years ago
por: Dooms, Marc M.
Publicado: (2015)

Rare Diseases and Orphan Drugs Accessibility in Bosnia and Herzegovina
por: Guzvic, Vladmiri, et al.
Publicado: (2018)

The impact of the rare disease and Orphan Drug Act in Taiwan
por: Hsiang, Ning-Chun, et al.
Publicado: (2021)

Rare pulmonary disease and orphan drugs: a path to the future
por: Harari, Sergio, et al.
Publicado: (2019)

Rare disease patients in India are rarely involved in international orphan drug trials
por: Chakraborty, Monoswi, et al.
Publicado: (2022)

A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act
por: Fermaglich, Lewis J., et al.
Publicado: (2023)

Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives
por: Harris, Emily
Publicado: (2018)

Rare diseases: Canada’s “research orphans”
por: Gupta, Samir
Publicado: (2012)

Will Gene Editing Orphanize Rare Diseases?
por: Mann, Douglas L.
Publicado: (2023)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

Ethical Questions Linked to Rare Diseases and Orphan Drugs – A Systematic Review
por: Kacetl, Jaroslav, et al.
Publicado: (2020)

Criteria to define rare diseases and orphan drugs: a systematic review protocol
por: Abozaid, Ghada Mohammed, et al.
Publicado: (2022)

Educational aspects of rare and orphan lung diseases
por: Alfaro, Tiago M., et al.
Publicado: (2021)

Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders
por: Ries, Markus, et al.
Publicado: (2015)

Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study
por: Gorini, Francesca, et al.
Publicado: (2022)

Financing of Rare Diseases and Orphan Drugs in A Sanctioned Country: A Qualitative Study
por: Naghdi, Seyran, et al.
Publicado: (2022)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

ORCAE-AOCC: A Centralized Portal for the Annotation of African Orphan Crop Genomes
por: Yssel, Anna E. J., et al.
Publicado: (2019)

Orphandev, French Clinical Trials Network dedicated to Orphan drugs and therapeutics development for rare diseases
por: Adjibi, Yolande, et al.
Publicado: (2010)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
por: Czech, Marcin, et al.
Publicado: (2020)

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
por: Harari, Sergio, et al.
Publicado: (2015)

Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: The market expansion of eculizumab
por: Caetano, Rosângela, et al.
Publicado: (2021)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Compassionate use of orphan drugs
por: Hyry, Hanna I., et al.
Publicado: (2015)

Orphan drugs: Indian perspective
por: Kumar, Harish, et al.
Publicado: (2017)

Generalized pustular psoriasis: the case for rare disease and orphan designation
por: Koren, Jan, et al.
Publicado: (2022)

Orphan rare diseases - The unified airways and its importance for the otorhinolaryngologist
por: Sakano, Eulalia, et al.
Publicado: (2022)

FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
por: Michaeli, Thomas, et al.
Publicado: (2023)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs
por: Cui, Yazhou, et al.
Publicado: (2015)

An Early Examination of Access to Select Orphan Drugs Treating Rare Diseases in Health Insurance Exchange Plans
por: Robinson, Sandy W., et al.
Publicado: (2014)

The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
por: Arnold, Renée J.G., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_co24k5b44ki531evaam0qd69dq